ALKE.NS
ALKEM LABORATORIES LTD maintains a strong capital structure with a debt-to-equity ratio of 0.12, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 2.76, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk. In terms of profitability, the company's return on equity (ROE) is 18.07%, and its return on assets (ROA) is 12.24%. These figures suggest that the company is generating strong returns relative to its equity and asset base. The gross profit margin is 62.64%, and the operating margin is 16.72%, both of which are indicative of efficient cost management and pricing power. The company's revenue is primarily concentrated in the Indian market, with no significant international operations disclosed. This concentration may expose the company to regional economic and regulatory risks. The company's revenue concentration is high, with no diversification across multiple geographic regions. The company's growth trajectory is positive, with a strong operating cash flow of 19,128.4 million INR and a free cash flow of 13,923 million INR. These figures suggest that the company has the financial flexibility to reinvest in its operations, pay dividends, or reduce debt. The capital expenditure of -6,756.2 million INR indicates that the company is investing in its long-term growth. The company faces a medium liquidity risk, as indicated by its negative net cash position after subtracting total debt. The dilution risk is low, with no significant dilution potential reported. The company's risk assessment highlights the need for continued monitoring of its liquidity position to ensure it remains financially stable. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's recent performance and financial health are in line with its historical trends, with no major disruptions reported.
Business. ALKEM LABORATORIES LTD is a pharmaceutical company that develops, manufactures, and markets a range of generic and branded drugs, primarily in the Indian market.
Classification. The company is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.
- ALKEM LABORATORIES LTD has a strong capital structure with a low debt-to-equity ratio and a healthy current ratio.
- The company generates strong returns on equity and assets, indicating efficient use of capital.
- Revenue is concentrated in the Indian market, which may expose the company to regional risks.
- The company has a positive operating and free cash flow, providing financial flexibility for growth and debt reduction.
- The company faces a medium liquidity risk due to its negative net cash position after subtracting total debt.
- The dilution risk is low, and the company's risk assessment highlights the need for continued liquidity monitoring.
- # RATIONALES
- **margin_outlook_rationale**: The company's gross and operating margins are expected to remain stable due to efficient cost management and pricing power.
- Net cash is negative after subtracting total debt.